Shots:

• Richter signed an asset purchase agreement with Janssen for Evra transdermal contraceptive patch assets outside the US. The total deal value is $263.5M
• The companies also signed a transitional business license agreement and a series of other related agreements to run the business without interruption during the period required to transfer the marketing authorizations to Richter
• The acquisition will strengthen Richter’s position in women’s healthcare and boost its existing female healthcare franchise globally. Evra (qw) is the first transdermal hormonal patch to be approved- as well as the first non-invasive form of birth control that- when used correctly- is 99% effective

 ­ Ref: Richter | Image: Janssen